Rachel C Brennan1, Ibrahim Qaddoumi2, Catherine A Billups3, Tammy L Free4, Barrett G Haik5, Carlos Rodriguez-Galindo6, Matthew W Wilson7. 1. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 2. Department of Oncology, St Jude Children's Research Hospital, Memphis, Tennessee, USA Department of Pediatrics, University of Tennessee Health Science Center, Memphis, Tennessee, USA. 3. Department of Biostatistics, St Jude Children's Research Hospital, Memphis, Tennessee, USA. 4. Department of Information Sciences, St Jude Children's Research Hospital, Memphis, Tennessee, USA. 5. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee, USA. 6. Dana-Farber/Children's Hospital Cancer Center and Harvard Medical School, Boston, Massachusetts, USA. 7. Department of Ophthalmology, University of Tennessee Health Science Center, Memphis, Tennessee, USA Department of Surgery, St Jude Children's Research Hospital, Memphis, Tennessee, USA Department of Pathology, St Jude Children's Research Hospital, Memphis, Tennessee, USA.
Abstract
AIMS: To compare high-risk histopathology of eyes with primary versus secondary enucleation from patients with retinoblastoma. PATIENTS AND METHODS: A retrospective histopathology review identified 207 eyes enucleated from 202 patients between March 1997 and August 2013. Our review considered high-risk histopathological features to include extraocular disease or invasion of the anterior chamber, iris, ciliary body, choroid (massive), postlaminar optic nerve or sclera. RESULTS: Most eyes (144, 70%) were primarily enucleated; 63 (30%) were secondarily enucleated after neoadjuvant therapy. The primary enucleation group had more advanced disease (Reese-Ellsworth group V: 95% vs 59%; International Classification Group D/E: 97% vs 59%; p<0.001). The incidence of high-risk histopathology features was similar between groups (32% vs 21%, n=59; p=0.132). The type of prior therapy was not associated with high-risk histopathology features. Time to enucleation was longer for secondarily enucleated eyes with high-risk features. Choroid and postlaminar optic nerve invasion were more frequent in eyes primarily enucleated (p<0.001). Forty-six of the 59 (78%) patients with high-risk features received adjuvant chemotherapy and/or external beam radiation therapy. Three patients who received primary enucleation and adjuvant therapy died of metastatic recurrence. CONCLUSIONS: Despite the more favourable classification of eyes treated with neoadjuvant therapy, the risk of high-risk histopathology features at enucleation was comparable with eyes undergoing primary enucleation. Delayed enucleation was associated with these features, and the majority of patients required further adjuvant therapy. Caution must be exercised in treating recalcitrant intraocular retinoblastoma to promptly pursue definitive enucleation in an effort to minimise further treatment exposures and metastases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
AIMS: To compare high-risk histopathology of eyes with primary versus secondary enucleation from patients with retinoblastoma. PATIENTS AND METHODS: A retrospective histopathology review identified 207 eyes enucleated from 202 patients between March 1997 and August 2013. Our review considered high-risk histopathological features to include extraocular disease or invasion of the anterior chamber, iris, ciliary body, choroid (massive), postlaminar optic nerve or sclera. RESULTS: Most eyes (144, 70%) were primarily enucleated; 63 (30%) were secondarily enucleated after neoadjuvant therapy. The primary enucleation group had more advanced disease (Reese-Ellsworth group V: 95% vs 59%; International Classification Group D/E: 97% vs 59%; p<0.001). The incidence of high-risk histopathology features was similar between groups (32% vs 21%, n=59; p=0.132). The type of prior therapy was not associated with high-risk histopathology features. Time to enucleation was longer for secondarily enucleated eyes with high-risk features. Choroid and postlaminar optic nerve invasion were more frequent in eyes primarily enucleated (p<0.001). Forty-six of the 59 (78%) patients with high-risk features received adjuvant chemotherapy and/or external beam radiation therapy. Three patients who received primary enucleation and adjuvant therapy died of metastatic recurrence. CONCLUSIONS: Despite the more favourable classification of eyes treated with neoadjuvant therapy, the risk of high-risk histopathology features at enucleation was comparable with eyes undergoing primary enucleation. Delayed enucleation was associated with these features, and the majority of patients required further adjuvant therapy. Caution must be exercised in treating recalcitrant intraocular retinoblastoma to promptly pursue definitive enucleation in an effort to minimise further treatment exposures and metastases. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Junyang Zhao; Helen Dimaras; Christine Massey; Xiaolin Xu; Dongsheng Huang; Bin Li; Helen S L Chan; Brenda L Gallie Journal: J Clin Oncol Date: 2011-01-31 Impact factor: 44.544
Authors: D L Friedman; B Himelstein; C L Shields; J A Shields; M Needle; D Miller; G R Bunin; A T Meadows Journal: J Clin Oncol Date: 2000-01 Impact factor: 44.544
Authors: C L Shields; J A Shields; M Needle; P de Potter; S Kheterpal; A Hamada; A T Meadows Journal: Ophthalmology Date: 1997-12 Impact factor: 12.079
Authors: Santosh G Honavar; Arun D Singh; Carol L Shields; Anna T Meadows; Hakan Demirci; Jacqueline Cater; Jerry A Shields Journal: Arch Ophthalmol Date: 2002-07
Authors: Swathi Kaliki; Carol L Shields; Duangnate Rojanaporn; Saad Al-Dahmash; John P McLaughlin; Jerry A Shields; Ralph C Eagle Journal: Ophthalmology Date: 2013-02-08 Impact factor: 12.079
Authors: Jonathan W Kim; Sona N Shah; Sarah Green; John O'Fee; Benita Tamrazi; Jesse L Berry Journal: Acta Ophthalmol Date: 2019-08-17 Impact factor: 3.761
Authors: Ankit Singh Tomar; Paul T Finger; Brenda Gallie; Tero T Kivelä; Ashwin Mallipatna; Chengyue Zhang; Junyang Zhao; Matthew W Wilson; Rachel C Brennan; Michala Burges; Jonathan Kim; Jesse L Berry; Rima Jubran; Vikas Khetan; Suganeswari Ganesan; Andrey Yarovoy; Vera Yarovaya; Elena Kotova; Denis Volodin; Yacoub A Yousef; Kalle Nummi; Tatiana L Ushakova; Olga V Yugay; Vladimir G Polyakov; Marco A Ramirez-Ortiz; Elizabeth Esparza-Aguiar; Guillermo Chantada; Paula Schaiquevich; Adriana Fandino; Jason C Yam; Winnie W Lau; Carol P Lam; Phillipa Sharwood; Sonia Moorthy; Quah Boon Long; Vera Adobea Essuman; Lorna A Renner; Ekaterina Semenova; Jaume Català-Mora; Genoveva Correa-Llano; Elisa Carreras Journal: Ophthalmology Date: 2022-04-15 Impact factor: 14.277
Authors: John T Lucas; Rose McGee; Catherine A Billups; Ibrahim Qaddoumi; Thomas E Merchant; Rachel C Brennan; Jiangrong Wu; Matthew W Wilson Journal: Br J Ophthalmol Date: 2018-06-28 Impact factor: 4.638
Authors: Mohammed M Abusayf; Hind M Alkatan; Sahar Elkhamary; Saleh A Almesfer; Azza M Y Maktabi Journal: BMC Ophthalmol Date: 2020-09-29 Impact factor: 2.209